Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met resistance mutation. We assessed the efficacy and safety of osimertinib in patients with EGFR Thr790Met-positive non-small-cell lung cancer (NSCLC), who had progressed after previous therapy with an approved EGFR tyrosine-kinase inhibitor.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Dec 2016

Volume: 17

Issue: 12

Affiliations

[1 ] The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada. Electronic address: ggoss@toh.on.ca.

[2 ] Department of Chest Medicine, Taipei-Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan.

[3 ] Princess Margaret Cancer Centre, Toronto, ON, Canada.

[4 ] UC San Diego, Moores Cancer Center, La Jolla, CA, USA.

[5 ] Seoul National University, Bundang Hospital, Seongnam, South Korea.

[6 ] Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, National Yang-Ming University, Taipei, Taiwan.

[7 ] Perugia University Medical School, Perugia, Italy.

[8 ] Hyogo Cancer Center, Akashi, Japan.

[9 ] University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada.

[10 ] Aichi Cancer Center Hospital, Nagoya, Japan.

[11 ] National Cancer Center, Goyang-si, Republic of Korea.

[12 ] La Fe University Hospital, Valencia, Spain.

[13 ] Duke University Medical Center, Durham, NC, USA.

[14 ] The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

[15 ] The Catholic University of Korea, South Korea.

[16 ] Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

[17 ] AstraZeneca, Cambridge, UK.

[18 ] AstraZeneca, Alderley Park, UK.

[19 ] Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

Article

Publisher Item ID: S1470-2045(16)30508-3

DOI: 10.1016/S1470-2045(16)30508-3

PubMed ID: 27751847

SO-VID: 5b69c94d-a165-4893-9132-008bd33f3588

History

Data availability:

Comments

Comment on this article

scite_

Cited by 240

See all cited by

- Version 1